Cancer Research Meeting Calendar  Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsuiki, H.
Right arrow Articles by Wong, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsuiki, H.
Right arrow Articles by Wong, A. J.
[Cancer Research 63, 250-255, January 2003]
© 2003 American Association for Cancer Research


Tumor Biology

Constitutively Active Forms of c-Jun NH2-terminal Kinase Are Expressed in Primary Glial Tumors1

Hiromasa Tsuiki2, Mehdi Tnani2, Isamu Okamoto, Lawrence C. Kenyon, David R. Emlet, Marina Holgado-Madruga, Irene S. Lanham, Christopher J. Joynes, Kim T. Vo and Albert J. Wong3

Departments of Microbiology and Immunology, Kimmel Cancer Institute [H. T., M. T., I. O., D. R. E., M. H-M., I. S. L., C. J. J., K. T. V., A. J. W.], and Pathology, Anatomy, and Cell Biology [L. C. K.], Thomas Jefferson University, Philadelphia, Pennsylvania 19107

The c-Jun NH2-terminal kinases (JNKs) have a role both in promoting apoptosis and tumorigenesis.The JNKs are encoded by three separate genes (JNK1, 2, and 3), whichare spliced alternatively to create 10 JNK isoforms that are either Mr 55,000 or 46,000 in size. However, the functional significance and distinct role for each splice variant remains unclear. We have noted previously that 86% of primary human glial tumors show activation of almost exclusively the Mr 55,000 isoforms of JNK. To further study which isoforms are involved, we constructed glutathione S-transferase fusion proteins for all 10 JNK isoforms and examined kinase activity with or without the activating upstream kinase. Surprisingly, five JNK isoforms demonstrate autophosphorylation activity, and in addition, all four JNK2 isoforms (either Mr 55,000 or 46,000) show a high basal level of substrate kinase activity in the absence of the upstream kinase, especially a Mr 55,000 JNK2 isoform. Examination revealed autophosphorylation activity at the T-P-Y motif, which is critical for JNK activation, because a mutant lacking the dual phosphorylation sites did not show autophosphorylation or basal kinase activity. Using green fluorescence protein-JNK expression vectors, transient transfection into U87MG cells demonstrates that although the JNK1 isoforms localize predominantly to the cytoplasm, the JNK2 isoforms localize to the nucleus and are phosphorylated, confirming the constitutive activation seen in vitro. We then examined which JNK isoforms are active in glial tumors by performing two-dimensional electrophoresis. This revealed that the Mr 55,000 isoforms of JNK2 are the principal active JNK isoforms present in tumors. Collectively, these results suggest that these constitutively active JNK isoforms play a significant role in glial tumors. Aside from epidermal growth factor receptor vIII, this is the only other kinase that has been shown to be basally active in glioma. The presence of constitutively active JNK isoforms may have implications for the design of inhibitors of the JNK pathway.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
R. T. Nitta, A. H. Chu, and A. J. Wong
Constitutive Activity of JNK2{alpha}2 Is Dependent on a Unique Mechanism of MAPK Activation
J. Biol. Chem., December 12, 2008; 283(50): 34935 - 34945.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
T. Boutros, E. Chevet, and P. Metrakos
Mitogen-Activated Protein (MAP) Kinase/MAP Kinase Phosphatase Regulation: Roles in Cell Growth, Death, and Cancer
Pharmacol. Rev., September 1, 2008; 60(3): 261 - 310.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Mangiola, G. Lama, C. Giannitelli, P. De Bonis, C. Anile, L. Lauriola, G. La Torre, G. Sabatino, G. Maira, M. Jhanwar-Uniyal, et al.
Stem Cell Marker Nestin and c-Jun NH2-Terminal Kinases in Tumor and Peritumor Areas of Glioblastoma Multiforme: Possible Prognostic Implications
Clin. Cancer Res., December 1, 2007; 13(23): 6970 - 6977.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Y. Zhang, A. E. Adams, T. W. Ridky, S. Tao, and P. A. Khavari
Tumor Necrosis Factor Receptor 1/c-Jun-NH2-Kinase Signaling Promotes Human Neoplasia
Cancer Res., April 15, 2007; 67(8): 3827 - 3834.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. Zhong, J. Fromm, and D. L. Johnson
TBP Is Differentially Regulated by c-Jun N-Terminal Kinase 1 (JNK1) and JNK2 through Elk-1, Controlling c-Jun Expression and Cell Proliferation
Mol. Cell. Biol., January 1, 2007; 27(1): 54 - 64.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Nielsen, J. Thastrup, T. Bottzauw, M. Jaattela, and T. Kallunki
c-Jun NH2-Terminal Kinase 2 Is Required for Ras Transformation Independently of Activator Protein 1
Cancer Res., January 1, 2007; 67(1): 178 - 185.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Cui, S.-Y. Han, C. Wang, W. Su, L. Harshyne, M. Holgado-Madruga, and A. J. Wong
c-Jun NH2-Terminal Kinase 2{alpha}2 Promotes the Tumorigenicity of Human Glioblastoma Cells.
Cancer Res., October 15, 2006; 66(20): 10024 - 10031.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Rosenzweig, A. Ziv-Av, C. Xiang, W. Lu, S. Cazacu, D. Taler, C. G. Miller, R. Reich, Y. Shoshan, Y. Anikster, et al.
Related to Testes-Specific, Vespid, and Pathogenesis Protein-1 (RTVP-1) Is Overexpressed in Gliomas and Regulates the Growth, Survival, and Invasion of Glioma Cells.
Cancer Res., April 15, 2006; 66(8): 4139 - 4148.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. M. Whang, Y. H. Kim, J. S. Kim, and Y. D. Yoo
RASSF1A Suppresses the c-Jun-NH2-Kinase Pathway and Inhibits Cell Cycle Progression
Cancer Res., May 1, 2005; 65(9): 3682 - 3690.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Cui, M. Holgado-Madruga, W. Su, H. Tsuiki, P. Wedegaertner, and A. J. Wong
Identification of a Specific Domain Responsible for JNK2{alpha}2 Autophosphorylation
J. Biol. Chem., March 18, 2005; 280(11): 9913 - 9920.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Reiley, M. Zhang, and S.-C. Sun
Negative Regulation of JNK Signaling by the Tumor Suppressor CYLD
J. Biol. Chem., December 31, 2004; 279(53): 55161 - 55167.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. Tonini, C. Gabellini, L. Bagella, G. D'Andrilli, V. Masciullo, G. Romano, G. Scambia, G. Zupi, and A. Giordano
pRb2/p130 Decreases Sensitivity to Apoptosis Induced by Camptothecin and Doxorubicin but not by Taxol
Clin. Cancer Res., December 1, 2004; 10(23): 8085 - 8093.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. A. MacCorkle and T.-H. Tan
Inhibition of JNK2 Disrupts Anaphase and Produces Aneuploidy in Mammalian Cells
J. Biol. Chem., September 17, 2004; 279(38): 40112 - 40121.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.